CEACAM5 and prostate carcinoma: CEACAM5 expression was consistently below 0.9 for all stages of prostate cancer and was not greater than expression levels in non-neoplastic prostate tissue (0.5 ± 1.0; P = NS), suggesting that prostate tumors would not be responsive to treatment with either anti-CEACAM5 or anti-CEACAM6 antibody therapies.